Status:
UNKNOWN
Study for Quantitative Analysis of the Recovered COVID-19 Patients by 18F-FDG-PET/CT
Lead Sponsor:
Fifth Affiliated Hospital, Sun Yat-Sen University
Conditions:
PET/CT
COVID-19
Eligibility:
All Genders
18-85 years
Brief Summary
In this study, clinically cured patients with severe COVID-19 were used to evaluate the therapeutic effect of COVID-19 and the recovery and health status of patients over time with highly sensitive PE...
Detailed Description
Covid-19 (Corona Virus Disease 2019, COVID-19), referred to as "COVID-19", refers to the pneumonia caused by novel Coronavirus 2019 (2019-NCOV/SARS-COV-2) infection. The clinical manifestations of the...
Eligibility Criteria
Inclusion
- Screening of clinically cured patients with severe COVID-19:
- Patients with severe COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria;
- Age \> 18 years, age \< 85 years, no gender restriction;
- All had received COVID-19 drug therapy;
- ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min;
- Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
- Screening of clinically cured patients with mild COVID-19:
- Patients with mild COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria;
- Age \> 18 years, age \< 85 years, no gender restriction;
- All had received COVID-19 drug therapy;
- ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min;
- Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
Exclusion
- Poorly controlled diabetics (fasting glucose level and GT;200 mg/dL);
- Any other malignancy within 5 years;
- Breastfeeding and/or pregnant women;
- Those who are prone to severe bleeding;
- Recent severe hemoptysis, severe cough, dyspnea or patients cannot cooperate;
- Severe emphysema, pulmonary congestion and pulmonary heart disease;
- The researchers believe that the subjects may not be able to complete the study or comply with the requirements of the study.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04519255
Start Date
July 1 2020
End Date
July 31 2023
Last Update
February 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hongjun Jin
Zhuhai, Guangzhou, China, 519000